Ambrx, Roche In Technology Deal

Roche and San Diego-based Ambrx today announced that the two companies have entered into a collaboration to develop next generation proteins and peptides using Ambrx technology. Roche will fund research and development of the products, and retain worldwide commercialization rights. Ambrx will receive license fees and royalties on product sales. Roche Venture Fund will also make an equity investment in Ambrx as part of the deal. Ambrx is backed by 5AM Ventures, Tavistock, Versant Ventures, CMEA, Aravis Ventures, and others. Ambrx genetically engineers proteins using amino acid building blocks. More information »